In Vivo Pharmacodynamic Activity of Tomopenem (formerly CS-023) against Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus in a Murine Thigh Infection Model
- 1 December 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (12) , 5298-5302
Abstract
Tomopenem (formerly CS-023) is a novel carbapenem with broad-spectrum activities against diverse hospital pathogens, including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). We examined the in vivo pharmacodynamic characteristics of tomopenem against P. aeruginosa and MRSA by using a neutropenic murine thigh infection model with P. aeruginosa 12467 (MIC, 1 μg/ml) and MRSA 12372 (MIC, 2 μg/ml). The mice had 10 6 to 10 7 CFU/thigh of each strain 2 h after inoculation and were treated for 24 h with a fractionated administration of tomopenem given at intervals of 3, 6, 12, and 24 h. The serum protein binding of tomopenem was 17.4%. The efficacy of tomopenem in both infection models was enhanced by frequent dosing, which indicates that the efficacy is driven by the time above MIC ( T MIC ). In a sigmoid model, the cumulative percentages of the 24-h period that the concentrations of free, unbound fractions of the drug exceeded the MIC under steady-state pharmacokinetic conditions ( f % T MIC s) were best correlated with efficacy when R 2 was 0.79 and 0.86 against P. aeruginosa and MRSA, respectively. Other pharmacokinetic and pharmacodynamic (PK-PD) indexes for the free, unbound fractions, the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC) and the maximum concentration of the drug in serum divided by the MIC ( C max /MIC), showed poor correlation with efficacy when R 2 was ≤0.42. The f % T MIC values required for a static effect, 1-log kill, and 2-log kill against P. aeruginosa were 29, 39, and 51, respectively, which were similar to those for meropenem, for which the values were 24, 33, and 45, respectively. Against MRSA, the values for tomopenem were 27, 35, and 47. In conclusion, the pharmacodynamic characteristics of tomopenem were similar to those of meropenem against P. aeruginosa , and there was no difference between the target values for P. aeruginosa and MRSA required for efficacy in this study.Keywords
This publication has 22 references indexed in Scilit:
- In vitro postantibiotic effects of tomopenem (CS-023)against Staphylococcus aureus and Pseudomonas aeruginosaJournal of Medical Microbiology, 2010
- Pharmacodynamics of SMP-601 (PTZ601) against Vancomycin-Resistant Enterococcus faecium and Methicillin-Resistant Staphylococcus aureus in Neutropenic Murine Thigh Infection ModelsAntimicrobial Agents and Chemotherapy, 2009
- In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2008
- Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2008
- In Vivo Pharmacodynamic Profiling of Doripenem againstPseudomonas aeruginosaby Simulating Human ExposuresAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamics of RWJ-54428 against Staphylococcus aureus , Streptococcus pneumoniae , and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection ModelAntimicrobial Agents and Chemotherapy, 2008
- Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh ModelAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Healthy Male Caucasian VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic TargetAntimicrobial Agents and Chemotherapy, 2006
- In Vitro and In Vivo Antibacterial Activities of CS-023 (RO4908463), a Novel Parenteral CarbapenemAntimicrobial Agents and Chemotherapy, 2005